You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company had previously declared Chapter 11 bankruptcy, which would have enabled it to reorganize to stay afloat and pay its creditors over time.
Microbiome testing firm uBiome has filed for bankruptcy months after the FBI searched its offices as part of an investigation into its billing practices.
The San Francisco-based microbial genomics firm will sell off its product lines, testing labs, IP, and data within the next three months.
The Wall Street Journal examines billing codes used by uBiome.
Business Insider reports that uBiome halted the sale and testing of its SmartJane and SmartGut tests.
The moves come in the wake of an FBI search of the company's San Francisco office as part of an investigation into its billing practices.
The Wall Street Journal reports that the Federal Bureau of Investigation has searched uBiome's office as part of an inquiry into its billing practices.
The partners aim to determine whether the microbiome can be used to predict patient responses to certain inflammatory bowel disease therapies.
The company, which employs 300 people, axed 30 jobs in the US and 25 jobs from its overseas operations as it refocuses on therapeutic development.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.